Olivier Micheau is a graduate of the Universities of Central Lancashire, Preston, UK (B.Sc. Biochemistry), Paul Sabatier, Toulouse (M.Sc. Genetics) and Burgundy (Ph.D. Cellular and Molecular Biology). After a post-doc in Switzerland with Professor Jurg Tschopp at the Institute of Biochemistry (Lausannes), he was recruited he was recruited by the French National Institute for Health and Medical Research (INSERM) in 2003 as a research fellow, then research director in the U517/U866/U1231 research center (Dijon), headed by Pr Eric Solary, Dr Laurent Lagrost and now Pr François Ghiringhelli. His research interests, centered on TNF receptor members, have led to several important discoveries, including cross-talks between TNF receptors such as Fas and conventional chemotherapeutic drugs (Micheau et al. 1997and 1999) or elucidation of the molecular mechanisms underlying TNFR1 pleiotropic signaling (Micheau et al, 2001 and 2003). His actual interest is to further understand TRAIL signal transduction in order to optimize TRAIL-based antitumor therapeutic strategies (Mérino et al. 2006; Morizot et al. 2011; Jacquemin et al. 2012; Zakaria et al. 2015; Dufoura et al. 2017;Dufourb et al. 2017; Dubuisson et al. 2019; Belkhala et al. 2019).
